MOG-IgG testing strategies in accordance with the 2023 MOGAD criteria: A clinico-laboratory assessment

Introduction
This database includes the raw data linked with the paper "MOG-IgG testing strategies in accordance with the 2023 MOGAD criteria: A clinico-laboratory assessment " to be published on "Journal of Neurology Neurosurgery and Psychiatry". 
In this paper, we reported clinical, radiological and laboratory data concerning thirty-eight individuals diagnosed with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) to assess the impact of the criteria-based MOG-IgG testing in MOGAD diagnosis. 
Methods
Thirty-eight serum samples of MOG-IgG1-positive MOGAD patients were titred on MOG-IgG LCBA and FCBA, and the presence of supporting features for MOGAD assessed. MOGAD criteria were evaluated in three testing scenarios: a) FCBA without titration; b) FCBA with titration; c) LCBA with titration.
Results (in brief)
FCBA without titration failed to reach MOGAD diagnosis in 11/38 patients (28.9%, negative results in 5, lack of supporting features in 6). Patients with unconfirmed diagnosis had optic neuritis (ON, n=8), or transverse myelitis (TM, n=3). FCBA with titration allowed MOGAD diagnosis in 4 additional patients. Correlation between LCBA and FCBA titres was moderate (Spearman's rho 0.6, p<0.001).